sciencebriefs
13:00in productionCh. 1 · From a mould extract to a cured mouse/ 13:00 · ceiling 15 min
Medicine · Engineering

History of penicillin

Howard Florey and Ernst Chain's Oxford team, aided by a mould found on a Peoria cantaloupe, turned Fleming's decade-old observation into billions of units of penicillin a year, though Britain's refusal to patent the method cost it years of royalties.

From 1939, Howard Florey assembled a team at Oxford, including Ernst Chain and Norman Heatley, that purified enough penicillin to cure infected mice in May 1940 and, in February 1941, to treat a human patient, Albert Alexander, whose initial recovery ended in death only because supplies ran out. Florey and Heatley then travelled to the United States in 1941 to find manufacturers, where a Peoria laboratory's deep-tank fermentation method and a higher-yielding mould strain found on a market cantaloupe let American production scale from a research curiosity to billions of units a year by 1944. Chain wanted to patent the production process to protect British interests, but Florey and British colleagues considered profiting from the discovery unethical, so American firms patented their methods instead, later forcing British manufacturers to pay them royalties, a decision whose costs became clear only once the antibiotic era Florey's team had done so much to launch was already under way.

MedicineEngineeringMedicineDiseaseMedicine across the network →
Chapters & takeaways6
  1. 0:08
    From a mould extract to a cured mouse

    In May 1940 Florey's Oxford team showed that mice given penicillin survived a lethal bacterial infection that killed untreated mice by the next morning.

  2. 2:10
    A human patient, and not enough drug

    The first human patient treated with penicillin in February 1941 recovered briefly before dying when the supply ran out, a limitation of scale rather than of the drug itself.

  3. 4:20
    A trip to America and a lucky cantaloupe

    Florey and Heatley's 1941 visit to a Peoria research laboratory led to deep-tank fermentation and, in 1943, a higher-yielding mould strain found on a market cantaloupe.

  4. 6:30
    Billions of units a year

    Wartime production scaled from 21 billion units in 1943 to an estimated 6,852 billion units in 1945, transforming penicillin from a scarce extract into a mass-produced drug.

  5. 8:40
    A patent decision Britain later regretted

    Florey's team chose not to patent penicillin production on ethical grounds, while American manufacturers did, leaving British firms paying royalties for years afterward.

  6. 10:50
    Why the industrial half of the story matters

    Worth understanding because turning a laboratory finding into a wartime staple took as much organisational and manufacturing effort as it took science.

Worth your time?

Yes. Study the whole thing.

4.5/ 5
What works
  • the vivid mouse experiment, a clear overnight contrast between treated survivors and untreated deaths
  • the concrete production numbers, tracking a jump from 21 billion to nearly 7,000 billion units across three wartime years
  • the honest inclusion of the patent decision's cost, rather than treating the non-patenting choice as an uncomplicated virtue
What does not
  • it does not fully weigh whether Florey's ethical stance on patenting was the right call given the royalties Britain later paid
  • it compresses the years of purification chemistry into a much shorter account than the industrial scale-up receives
Study it if
  • readers who think Fleming alone gets to take credit for penicillin
  • anyone curious how a wartime industrial effort actually scaled a drug from grams to tonnes
  • readers interested in the practical costs of a principled decision not to patent something
Skip it if
  • readers wanting the biochemistry of beta-lactam structure and resistance mechanisms
  • anyone after a single simple hero rather than a large, distributed effort across Oxford, Peoria and multiple manufacturers
The written brief3 min read

From a mould extract to a cured mouse

From 1939, Howard Florey assembled an interdisciplinary team at Oxford’s Sir William Dunn School of Pathology, including the biochemist Ernst Chain and the technician Norman Heatley, to investigate whether Alexander Fleming’s decade-old observation about a mould that killed bacteria could be turned into an actual medicine. The team developed methods for growing the mould, extracting the active compound with solvents, and using freeze-drying to preserve it without destroying its effect, working initially on a shoestring budget of a few hundred pounds from the Medical Research Council before securing further support from the Rockefeller Foundation. On 25 May 1940, Florey tested the purified extract by infecting eight mice with a virulent bacterial strain and treating four of them with penicillin; all four untreated mice died by the following morning, while the treated mice survived, a result Florey himself called something close to a miracle.

A human patient, and not enough drug

The team’s first human patient was Albert Alexander, an Oxford police officer with a severe facial infection, treated beginning in February 1941. Alexander’s condition improved dramatically at first, but the Oxford team could not produce enough penicillin to sustain the treatment through his full recovery, and he died in March, a death caused by a shortage of supply rather than any failure of the drug to work. The case demonstrated penicillin’s genuine therapeutic power while making painfully clear that laboratory quantities were nowhere near sufficient for real medical use, and it pushed the team to focus further trials on children, who required smaller doses of the still-scarce drug.

A trip to America and a lucky cantaloupe

Florey and Heatley travelled to the United States in June 1941 specifically to find manufacturers capable of producing penicillin at a scale Oxford’s small laboratory could not match, meeting officials at the Northern Regional Research Laboratory in Peoria, Illinois, where Robert Coghill proposed deep-tank fermentation as a route to mass production. A further breakthrough followed in 1943, when researchers searching worldwide for higher-yielding mould strains found one growing on a cantaloupe at a Peoria fruit market, a strain that substantially outperformed the original mould Fleming had first isolated and that was further improved through radiation-induced mutation in subsequent years.

Billions of units a year

Production scaled at a pace that had no precedent in pharmaceutical manufacturing: from an estimated 21 billion units in 1943, output rose to 1,663 billion units in 1944 and an estimated 6,852 billion units by 1945, driven by American companies including Pfizer, which built large fermentation tanks specifically for the purpose, and by British manufacturers such as Imperial Chemical Industries and Glaxo, whose combined weekly output rose from around 2 million units in mid-1942 to hundreds of millions of units by 1944. That scale-up let penicillin reach military hospitals during the 1944 to 1945 European campaign in large enough quantities to be used both to treat and to prevent infection, sharply reducing deaths from wound infections that had killed large numbers of soldiers in earlier conflicts.

A patent decision Britain later regretted

The rapid American scale-up came with a cost that fell on Britain. Chain wanted the production process patented to protect British commercial interests, but Florey and colleagues at British institutions regarded profiting from the discovery as improper, so the process went unpatented on the British side while American manufacturers patented their own deep-tank fermentation methods without the same reservations. That asymmetry later forced British pharmaceutical firms to pay royalties to American companies for methods that British and American scientists had developed together, a consequence that only became apparent once penicillin’s industrial value was fully established and that eventually prompted Britain to set up its own body for managing research royalties.

Why the industrial half of the story matters

This part of the penicillin story is worth understanding on its own terms because it shows how much organisational and industrial effort stood between a laboratory result and an actual wartime medicine: purifying the compound, finding a manufacturer willing to invest in production, discovering a better mould strain almost by chance on a market cantaloupe, and building fermentation tanks at a scale no one had previously needed for a pharmaceutical product. None of that diminishes Fleming’s original observation, but it makes clear that turning it into the antibiotic era required years of separate, difficult, and only partly scientific work, work whose patent decisions still had financial consequences long after the war that made penicillin’s mass production so urgent had ended.

Same field · Medicine4 of 88
8:44
Alexander Fleming
13:00
History of general anesthesia
13:00
Management of HIV/AIDS
13:00
Asepsis
Up next in Science

Pentaquark

2015 · 13:00

A wave of pentaquark sightings in 2003 collapsed entirely by 2008 once other experiments failed to replicate them, and it took the LHCb collaboration's accidental 2015 discovery, confirmed at 15-sigma significance, to establish the particle for real.

Play nextBack to Medicine
13:00